Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in progression between patients with very mild or mild baseline AD. METHODS: In this three-year follow-up of 115 ALSOVA study patients with clinical dementia ratings (CDR) of very mild (0.5) or mild (1) AD, we analyzed total CERAD-NB, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and Clinical Dementia Rating Sum of Boxes scores. Correlations were identified with efficacy parameters. RESULTS: Over three years, total CERAD-NB declined significantly in both groups. Annual change rates of total CERAD-NB were also significant. Total CERAD-NB revealed annual differences in cognition between study groups, while MMSE did not. Total CERAD-NB correlated well with other cognitive and global measures, but not with NPI. For almost two years, the CDR-0.5 group maintained a higher activities of daily living than the CDR-1 group exhibited at baseline. Furthermore, the CDR-0.5 group showed milder neuropsychiatric symptoms at the end of follow-up than the CDR-1 group showed at baseline. CONCLUSIONS: The CERAD total score is a suitable and sensitive follow-up tool in longitudinal AD trials. Cognition progression rates did not significantly differ between study groups; however, patients with very mild AD at baseline had milder neuropsychiatric symptoms after long-term follow-up. This emphasizes the importance of early diagnosis and assessment of neuropsychiatric symptoms at the diagnostic visit and during follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Welsh, K. A., Butters, N., Mohs, R. C., Beekly, D., Edland, S., Fillenbaum, G., & Heyman, A. (1994) · Neurology · doi:10.1212/wnl.44.4.609 · Cited by 951
Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P., Lyketsos, C. G., Welsh‐Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 780
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
A total score for the CERAD neuropsychological battery
Chandler, M. J., Lacritz, L. H., Hynan, L. S., Barnard, H. D., Allen, G., Deschner, M., Weiner, M. F., & Cullum, C. M. (2005) · Neurology · doi:10.1212/01.wnl.0000167607.63000.38 · Cited by 387
The CERAD Neuropsychologic Battery Total Score and the Progression of Alzheimer Disease
Rossetti, H. C., Munro Cullum, C., Hynan, L. S., & Lacritz, L. H. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181b76415 · Cited by 110 · cited 10×
“We found that the annual CERAD change significantly correlated with dementia severity and functional ability, as shown previously (Rossetti et al., 2010), but did not correlate with NPI scores.”
BackgroundMethodResultInfluentialStein, J., Luppa, M., Luck, T., Maier, W., Wagner, M., Daerr, M., van den Bussche, H., Zimmermann, T., Köhler, M., Bickel, H., et al. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318209dd08 · Cited by 35
Cited by
Speech-based automatic and robust detection of very early dementia
Satt, A., Hoory, R., König, A., Aalten, P., & Robert, P. H. (2014) · Interspeech 2014 · doi:10.21437/interspeech.2014-544 · Cited by 76
“Research shows that psychological treatment to AD patients, which begins at the very early stage of the disease, alleviates psychological and behavioral symptoms [2].”
BackgroundAguirre-Acevedo, D. C., Jaimes-Barragán, F., Henao, E., Tirado, V., Muñoz, C., Reiman, E. M., Tariot, P. N., Langbaum, J. B., & Lopera, F. (2016) · International Psychogeriatrics · doi:10.1017/s1041610215001660 · Cited by 25
Lima-Silva, T. B., Mioshi, E., Bahia, V. S., Cecchini, M. A., Cassimiro, L., Guimarães, H. C., Gambogi, L. B., Caramelli, P., Balthazar, M., Damasceno, B., et al. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720944239 · Cited by 18
Metadata
- Authors
- Hallikainen, I., Hänninen, T., Fraunberg, M., Hongisto, K., Välimäki, T., Hiltunen, A., Karppi, P., Sivenius, J., Soininen, H., & Koivisto, A. M.
- Venue
- International Psychogeriatrics
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 25
- Issue
- 8
- Pages
- 1335-1344
- ISSN
- 1041-6102 (ISSN-L)
- OpenAlex
- W2124594290
- Cited by
- 36
- References
- 7
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.